Posted by Michael Wonder on 23 Oct 2019
The district court rejected an appeal against Darzalex
21 October 2019 - TLV's decision to reject the grant application for Darzalex was appealed to the Administrative Court in Stockholm.
The company requested that Darzalex be included in the high-cost protection as combination therapy with bortezomib and dexamethasone. The company's appeal has been rejected by administrative law and the judgment has now gained legal force.
On November 24, 2017, TLV decided to reject the grant application for Darzalex. The company that markets Darzalex appealed TLV's decision to the Administrative Court in Stockholm.
